Niche HIV Vaccine AELIX Therapeutics operates as a clinical-stage biotech focused on a therapeutic HIV vaccine and has an exclusive license for the HTI immunogen, indicating a targeted solution with potential for strategic partnerships in HIV cure research and related immunotherapies.

Strategic Alliance History Historical collaborations with Gilead and ties to HIVACAT suggest openness to co-development and licensing opportunities, making them a candidate for in-licensing discussions, joint ventures, or research collaborations with large pharma and biotech biotech players.

Early-Stage Funding With funding around $15M and revenue under $1M, the company is in a capital-lean growth phase, presenting a clear need for partnerships, grant support, and potential investment or contract research opportunities to scale clinical programs.

Global IP License Worldwide exclusive license for HTI immunogen points to defensible IP and potential for license-out deals, co-development arrangements, or targeted regional partnerships to maximize reach and value of the HTI-based strategy.

Clinical to Commercial Path As a Barcelona-based, small team with a clinical-stage program, AELIX presents an opportunity for CRO/CMO services, regulatory affairs support, and patient-access/commercialization planning assistance as they transition from trials toward potential market entry.